Regorafenib

CAS 755037-03-7

Overview

Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase. Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition

Anant Labs manufacture and furnish high quality Regorafenib impurities for global markets. Our Regorafenib EP Impurities are used by API manufacturers and fully integrated pharmaceutical companies worldwide.

In Stock

Regorafenib

CAS 755037-03-7In Stock

Technical Data

CAS755037-03-7

Mol. FormulaC₂₁H₁₅ClF₄N₄O₃

Mol. Weight482.821 g/mol

IUPAC4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide

SMILESCNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F

InChIInChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)

InChI KeyFNHKPVJBJVTLMP-UHFFFAOYSA-N

Note: We are upgrading our system, Cat No will change.

Synonyms

Regorafenib755037-03-7BAY 73-4506StivargaRegorafenibumBAY73-4506BAY-73-4506REGORAFENIB ANHYDROUS4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide24T2A1DOYB